Skip to main content

Table 1 Association between METTL14 gene polymorphisms and Wilms tumor susceptibility

From: METTL14 gene polymorphisms decrease Wilms tumor susceptibility in Chinese children

Genotype

Cases (N = 403)

Controls (N = 1198)

Pa

Crude OR (95% CI)

P

Adjusted OR (95% CI) b

Pb

rs1064034 T > A (HWE = 0.715)

 TT

216 (53.60)

564 (47.08)

 

1.00

 

1.00

 

 TA

152 (37.72)

512 (42.74)

 

0.78 (0.61–0.99)

0.037

0.78 (0.61–0.99)

0.041

 AA

35 (8.68)

122 (10.18)

 

0.75 (0.50–1.13)

0.164

0.76 (0.51–1.15)

0.198

 Additive

  

0.035

0.83 (0.70–0.99)

0.035

0.83 (0.70–0.995)

0.044

 Dominant

187 (46.40)

634 (52.92)

0.024

0.77 (0.61–0.97)

0.024

0.78 (0.62–0.97)

0.029

 Recessive

368 (91.32)

1076 (89.82)

0.382

0.84 (0.57–1.24)

0.382

0.86 (0.58–1.27)

0.438

rs298982 G > A (HWE = 0.155)

 GG

321 (79.65)

873 (72.87)

 

1.00

 

1.00

 

 GA

66 (16.38)

292 (24.37)

 

0.62 (0.46–0.83)

0.001

0.62 (0.46–0.84)

0.002

 AA

16 (3.97)

33 (2.75)

 

1.32 (0.72–2.43)

0.375

1.32 (0.72–2.43)

0.373

 Additive

  

0.061

0.80 (0.64–1.01)

0.061

0.81 (0.64–1.02)

0.071

 Dominant

82 (20.35)

325 (27.13)

0.007

0.69 (0.52–0.90)

0.007

0.69 (0.53–0.91)

0.009

 Recessive

387 (96.03)

1165 (97.25)

0.220

1.46 (0.80–2.68)

0.223

1.46 (0.79–2.68)

0.225

rs62328061 A > G (HWE = 0.819)

 AA

281 (69.73)

830 (69.28)

 

1.00

 

1.00

 

 AG

109 (27.05)

333 (27.80)

 

0.97 (0.75–1.25)

0.796

0.97 (0.75–1.25)

0.812

 GG

13 (3.23)

35 (2.92)

 

1.10 (0.57–2.10)

0.780

1.12 (0.58–2.15)

0.736

 Additive

  

0.963

1.00 (0.81–1.23)

0.963

1.00 (0.81–1.24)

0.998

 Dominant

122 (30.27)

368 (30.72)

0.867

0.98 (0.77–1.25)

0.867

0.98 (0.77–1.26)

0.894

 Recessive

390 (96.77)

1163 (97.08)

0.757

1.11 (0.58–2.12)

0.757

1.13 (0.59–2.16)

0.714

rs9884978 G > A (HWE = 0.412)

 GG

252 (62.53)

758 (63.27)

 

1.00

 

1.00

 

 GA

131 (32.51)

384 (32.05)

 

1.03 (0.80–1.31)

0.836

1.03 (0.81–1.31)

0.826

 AA

20 (4.96)

56 (4.67)

 

1.07 (0.63–1.83)

0.791

1.06 (0.62–1.80)

0.826

 Additive

  

0.759

1.03 (0.85–1.25)

0.757

1.03 (0.85–1.25)

0.773

 Dominant

151 (37.47)

440 (36.73)

0.790

1.03 (0.82–1.30)

0.789

1.03 (0.82–1.30)

0.791

 Recessive

383 (95.04)

1142 (95.33)

0.814

1.07 (0.63–1.80)

0.814

1.05 (0.62–1.78)

0.851

rs4834698 T > C (HWE = 0.827)

 TT

107 (26.55)

329 (27.46)

 

1.00

 

1.00

 

 TC

193 (47.89)

594 (49.58)

 

1.00 (0.76–1.31)

0.995

0.99 (0.75–1.30)

0.921

 CC

103 (25.56)

275 (22.95)

 

1.15 (0.84–1.58)

0.379

1.14 (0.83–1.56)

0.425

 Additive

  

0.392

1.07 (0.92–1.26)

0.392

1.07 (0.91–1.25)

0.438

 Dominant

296 (73.45)

869 (72.54)

0.722

1.05 (0.81–1.35)

0.724

1.03 (0.80–1.34)

0.798

 Recessive

300 (74.44)

923 (77.05)

0.287

1.15 (0.89–1.50)

0.287

1.15 (0.88–1.49)

0.304

Combined effect of protective genotypes c

 0–4

322 (79.90)

875 (73.04)

 

1.00

 

1.00

 

 5

81 (20.10)

323 (26.96)

0.006

0.68 (0.52–0.90)

0.006

0.69 (0.52–0.91)

0.008

  1. OR Odds ratio, CI Confidence interval, HWE Hardy-Weinberg equilibrium
  2. aχ2 test for genotype distributions between Wilms tumor patients and controls
  3. bAdjusted for age and gender
  4. cProtective genotypes were carriers with rs1064034 TA/AA, rs298982 GA/AA, rs62328061 AG/AA, rs9884978 GA/GG and rs4834698 TT/TC